Early oncology studies are not smaller versions of late-phase trials. They are exploratory environments where teams build knowledge patient by patient and must be comfortable making decisions before certainty exists.

Clinical expertise remains essential in oncology leadership, but modern development demands more. Future executives must connect science with strategy, operations, data, teams, and patient impact.

Early oncology development is full of unknowns, and the greatest risks are not always the ones already on the checklist. Strong teams learn to look for what the study may not yet be showing them.